These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 1353239)
1. Sustained haematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromes. Kelsey SM; Newland AC; Cunningham J; Makin HL; Coldwell RD; Mills MJ; Grant IR Lancet; 1992 Aug; 340(8814):316-7. PubMed ID: 1353239 [No Abstract] [Full Text] [Related]
2. [Treatment of myelodysplastic syndrome with alfacalcidol]. Tagawa M; Ito H; Kuriyama K; Tomonaga M; Ichimaru M Gan To Kagaku Ryoho; 1987 Nov; 14(11):3160-2. PubMed ID: 3674901 [No Abstract] [Full Text] [Related]
3. [Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders]. Takahashi T; Ichiba S; Okuno Y; Sugiyama H; Sakai Y; Imura H; Iho S; Hoshino T; Suzuki A; Okada T Rinsho Ketsueki; 1989 Jan; 30(1):1-10. PubMed ID: 2716194 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic trial of hematological disorders with intermittent administration of high-dose 1-alpha-hydroxyvitamin D3. Imai Y; Tsutsumi M; Tsunenari T; Nishikawa M; Matsui T; Natazuka T; Fujita T Contrib Nephrol; 1991; 91():95-101. PubMed ID: 1800016 [TBL] [Abstract][Full Text] [Related]
5. A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study. Yoshida Y; Oguma S; Uchino H; Maekawa T; Nomura T Int J Clin Pharmacol Res; 1993; 13(1):21-7. PubMed ID: 8509233 [TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes. Akiyama N; Miyazawa K; Kanda Y; Tohyama K; Omine M; Mitani K; Ohyashiki K Leuk Res; 2010 Sep; 34(9):1151-7. PubMed ID: 20569983 [TBL] [Abstract][Full Text] [Related]
7. Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome. Motomura S; Fujisawa S; Tsunooka S; Fujimaki K; Mohri H; Okubo T Am J Hematol; 1996 Oct; 53(2):143-4. PubMed ID: 8892744 [No Abstract] [Full Text] [Related]
8. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)]. Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504 [No Abstract] [Full Text] [Related]
9. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635 [TBL] [Abstract][Full Text] [Related]
10. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Albitar S; Genin R; Fen-Chong M; Serveaux MO; Schohn D; Chuet C Nephrol Dial Transplant; 1997 Mar; 12(3):514-8. PubMed ID: 9075133 [TBL] [Abstract][Full Text] [Related]
11. Recommended dose of alfacacidol for osteoporosis. Bunyaratavej N J Med Assoc Thai; 2011 Oct; 94 Suppl 5():S7-9. PubMed ID: 22338919 [TBL] [Abstract][Full Text] [Related]
12. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Moe S; Wazny LD; Martin JE Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704 [TBL] [Abstract][Full Text] [Related]
13. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease. Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136 [TBL] [Abstract][Full Text] [Related]